Kalaris Therapeutics Inc (KLRS) 10-Year Financial Performance & Capital Metrics

KLRS • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutKalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.Show more

Revenue $0
EBITDA -$59M -319.4%
Net Income -$59M -299.8%
EPS (Diluted) -11.73 +72.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -172.12%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 10.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-25.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.35%

ROCE

10Y Avg-41.05%

5Y Avg-48.63%

3Y Avg-54.7%

Latest-98.06%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.35B	18.28	22.57	65.15%	42.87%	48.57%	2.53%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	86.21M	2.90	-0.23			-49.37%		0.24
INOInovio Pharmaceuticals, Inc.	112.67M	1.64	-0.42	-73.83%	-592.82%	-115.42%		0.17
ALGSAligos Therapeutics, Inc.	48.45M	9.05	-0.43	-74.6%	-32.68%	-120.37%
BRNSBarinthus Biotherapeutics plc	30.83M	0.76	-0.49	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.99M	1.16	-0.67			-126.11%		0.19
KLRSKalaris Therapeutics Inc	172.81M	9.24	-0.79			-170.84%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.14M	165K	0	0	0	0	0
Revenue Growth %	-	-0.85%	-1%	-	-	-	-
Cost of Goods Sold+	0	0	73K	1.12M	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	-73K	-1.12M	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-14.3%	1%	-	-
Operating Expenses+	4.73M	26.85M	71.24M	168.7M	14.01M	13.46M	55.26M
OpEx % of Revenue	4.17%	162.71%	-	-	-	-	-
Selling, General & Admin	3.03M	10.62M	21.65M	49.08M	2.24M	1.76M	42.92M
SG&A % of Revenue	2.67%	64.35%	-	-	-	-	-
Research & Development	1.7M	16.23M	49.59M	119.62M	11.76M	11.71M	12.34M
R&D % of Revenue	1.5%	98.36%	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-3.6M	-26.7M	-71.31M	-169.82M	-14.01M	-13.46M	-55.26M
Operating Margin %	-3.17%	-161.82%	-	-	-	-	-
Operating Income Growth %	-	-6.43%	-1.67%	-1.38%	0.92%	0.04%	-3.1%
EBITDA+	-2.43M	-26.68M	-71.24M	-168.7M	-15.25M	-14.01M	-58.77M
EBITDA Margin %	-2.14%	-161.71%	-	-	-	-	-
EBITDA Growth %	-	-9.98%	-1.67%	-1.37%	0.91%	0.08%	-3.19%
D&A (Non-Cash Add-back)	0	19K	73K	1.12M	0	0	0
EBIT	-2.43M	-23.84M	-69.78M	-170.96M	-15.25M	-14.01M	-58.77M
Net Interest Income+	56K	2.06M	1.33M	1.31M	-235K	-687K	5.49M
Interest Income	56K	2.06M	1.33M	1.31M	0	0	5.49M
Interest Expense	0	0	0	0	235K	687K	0
Other Income/Expense	1.17M	2.86M	1.52M	-1.14M	-1.48M	-1.24M	-3.51M
Pretax Income+	-2.43M	-23.84M	-69.78M	-170.96M	-15.48M	-14.7M	-58.77M
Pretax Margin %	-2.14%	-144.48%	-	-	-	-	-
Income Tax+	0	0	0	1.01M	0	0	0
Effective Tax Rate %	1%	1%	1%	1.01%	1%	1%	1%
Net Income+	-2.43M	-23.84M	-69.78M	-171.96M	-15.48M	-14.7M	-58.77M
Net Margin %	-2.14%	-144.48%	-	-	-	-	-
Net Income Growth %	-	-8.81%	-1.93%	-1.46%	0.91%	0.05%	-3%
Net Income (Continuing)	-2.43M	-23.84M	-69.78M	-171.96M	-15.48M	-14.7M	-58.77M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-2.88	-8.42	-59.67	-63.00	-50.62	-42.09	-11.73
EPS Growth %	-	-1.92%	-6.09%	-0.06%	0.2%	0.17%	0.72%
EPS (Basic)	-2.88	-8.42	-59.67	-63.00	-50.62	-42.09	-11.73
Diluted Shares Outstanding	2.83M	2.83M	1.17M	2.73M	3.33M	4.52M	5.01M
Basic Shares Outstanding	2.83M	2.83M	1.17M	2.73M	3.33M	4.52M	5.01M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.31M	127.31M	361.32M	253.35M	3.9M	3.33M	118.55M
Cash & Short-Term Investments	24.96M	126.08M	356.32M	248.12M	3.06M	3.17M	118.29M
Cash Only	24.96M	61.08M	122.66M	201.66M	3.06M	3.17M	118.29M
Short-Term Investments	0	64.99M	233.66M	46.46M	0	0	0
Accounts Receivable	302K	560K	450K	50K	0	0	0
Days Sales Outstanding	97.12	1.24K	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	51K	676K	4.54M	5.18M	0	0	257K
Total Non-Current Assets+	6K	12.11M	9.5M	33.25M	0	0	0
Property, Plant & Equipment	0	12.11M	9.5M	31.29M	0	0	0
Fixed Asset Turnover	-	0.01x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	852K	0	0	0
Other Non-Current Assets	6K	0	0	1.1M	0	0	0
Total Assets+	25.32M	139.42M	370.82M	286.59M	3.9M	3.33M	118.55M
Asset Turnover	0.04x	0.00x	-	-	-	-	-
Asset Growth %	-	4.51%	1.66%	-0.23%	-0.99%	-0.15%	34.57%
Total Current Liabilities+	3.74M	9.11M	12.29M	37.85M	5.69M	3.94M	5.24M
Accounts Payable	153K	630K	963K	8.36M	2.76M	2.36M	247K
Days Payables Outstanding	-	-	4.82K	2.73K	-	-	-
Short-Term Debt	0	3.07M	3.23M	6.59M	0	0	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0
Other Current Liabilities	921K	3.89M	4.79M	15.03M	296K	540K	1.96M
Current Ratio	6.77x	13.98x	29.39x	6.69x	0.69x	0.85x	22.63x
Quick Ratio	6.77x	13.98x	29.39x	6.69x	0.69x	0.85x	22.63x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	8.69M	5.46M	23.48M	28.48M	44.41M	0
Long-Term Debt	0	0	0	0	3.25M	0	0
Capital Lease Obligations	0	8.69M	5.46M	23.48M	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	25.23M	44.41M	0
Total Liabilities	3.74M	17.8M	17.76M	61.33M	34.17M	48.35M	5.24M
Total Debt+	0	11.76M	8.69M	30.07M	3.25M	0	0
Net Debt	-24.96M	-49.33M	-113.97M	-171.59M	194K	-3.17M	-118.29M
Debt / Equity	-	0.10x	0.02x	0.13x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-59.60x	-19.60x	-
Total Equity+	21.58M	121.62M	353.06M	225.27M	-30.27M	-45.02M	113.31M
Equity Growth %	-	4.64%	1.9%	-0.36%	-1.13%	-0.49%	3.52%
Book Value per Share	7.62	42.97	301.91	82.53	-9.08	-9.95	22.62
Total Shareholders' Equity	21.58M	121.62M	353.06M	225.27M	-30.27M	-45.02M	113.31M
Common Stock	0	0	7K	7K	0	0	0
Retained Earnings	-31.48M	-55.32M	-125.1M	-297.06M	-32.7M	-47.39M	-714.96M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	68K	-112K	-155K	0	0	-135K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.94M	-20.16M	-60.81M	-106.32M	-9.78M	-14.13M	-67.7M
Operating CF Margin %	1.71%	-122.15%	-	-	-	-	-
Operating CF Growth %	-	-11.37%	-2.02%	-0.75%	0.91%	-0.45%	-3.79%
Net Income	-2.43M	-23.84M	-69.78M	-171.96M	-15.48M	-14.7M	-58.77M
Depreciation & Amortization	0	19K	73K	1.12M	0	0	0
Stock-Based Compensation	0	0	0	0	271K	148K	0
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	967K	2.27M	9.93M	45.17M	2.04M	1.51M	16.37M
Working Capital Changes	3.41M	1.4M	-1.03M	19.35M	3.4M	-1.09M	-25.3M
Change in Receivables	170K	-258K	110K	400K	0	0	206K
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	601K	4.94M	2.73M	20.29M	1.83M	-402K	-28.86M
Cash from Investing+	0	-64.64M	-169.5M	185.98M	0	0	95M
Capital Expenditures	0	-339K	-235K	-26K	0	0	0
CapEx % of Revenue	-	2.05%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	22.87M	120.92M	291.98M	232K	12.78M	14.24M	21K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	0	0	0	5K	1.5M	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	1.94M	-20.49M	-61.05M	-106.34M	-9.78M	-14.13M	-67.7M
FCF Margin %	1.71%	-124.21%	-	-	-	-	-
FCF Growth %	-	-11.55%	-1.98%	-0.74%	0.91%	-0.45%	-3.79%
FCF per Share	0.69	-7.24	-52.20	-38.96	-2.93	-3.12	-13.52
FCF Conversion (FCF/Net Income)	-0.80x	0.85x	0.87x	0.62x	0.63x	0.96x	1.15x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-11.26%	-33.29%	-29.4%	-59.47%	-15.88%	-	-172.12%
Return on Invested Capital (ROIC)	-	-58.11%	-34.35%	-87.01%	-89.05%	-	-
Net Margin	-214.1%	-14447.88%	-	-	-	-	-
Debt / Equity	-	0.10x	0.02x	0.13x	-	-	-
Interest Coverage	-	-	-	-	-59.60x	-19.60x	-
FCF Conversion	-0.80x	0.85x	0.87x	0.62x	0.63x	0.96x	1.15x
Revenue Growth	-	-85.46%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Kalaris Therapeutics Inc (KLRS) grew revenue by 0.0% over the past year. Growth has been modest.

Kalaris Therapeutics Inc (KLRS) reported a net loss of $71.5M for fiscal year 2024.

Dividend & Returns

Kalaris Therapeutics Inc (KLRS) has a return on equity (ROE) of -172.1%. Negative ROE indicates the company is unprofitable.

Kalaris Therapeutics Inc (KLRS) had negative free cash flow of $38.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener